Telephone sharing button Contact Us mailbox sharing button wuxixdc_info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi XDC Releases Inaugural ESG Report
Demonstrating Leadership in Sustainability and Innovation
May. 29, 2024
WuXi XDC Releases Inaugural ESG Report
Demonstrating Leadership in Sustainability and Innovation

SHANGHAI, May 29, 2024—WuXi XDC, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and broader bioconjugates, announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report. The comprehensive document marks a significant milestone in the company’s journey to integrate sustainability with cutting-edge biotechnology.

 

Strengthening Governance: WuXi XDC has committed to robust governance practices that emphasize compliance, risk management, and ethical business conduct. In 2023, the company fortified its governance framework by enhancing its risk management and internal control systems, further embedding integrity and transparency across its operations.

 

Empowering Our People: Central to WuXi XDC’s success is its dedication to workforce development and diversity. With initiatives aimed at nurturing talent and fostering an inclusive workplace, the company continues to prioritize the well-being and professional growth of its over 1,100 team members, who come from diverse backgrounds. This approach not only empowers employees but also drives innovation within the company.

 

Environmental Sustainability: In 2023, WuXi XDC made significant strides in reducing its environmental impact. The company has achieved a 54% reduction in greenhouse gas emission intensity from its 2021 baseline, reflecting its resolve to combat climate change and promote sustainable operations throughout its global facilities.

 

Contributing to Society: WuXi XDC is deeply committed to having a positive effect on society. Through investments in community support, client empowerment, and collaborative industry advancement, WuXi XDC fosters a better future for all stakeholders. In 2023, the company’s efforts were recognized when it received the “Best CDMO” award at the annual ADC Awards, underscoring its leadership in the biopharmaceutical sector.

 

Dr. Jimmy Li, CEO of WuXi XDC and Chairman of the ESG Committee, commented, ” As part of our mission to link innovation to the advancement of global health, the release of our first ESG report is a pivotal step. It encapsulates our efforts to integrate sustainable practices into our core business strategy – ensuring that we not only lead in technology but also in corporate responsibility – and is a testament to our ongoing commitment to excellence and leadership in the biopharmaceutical industry, providing a transparent overview of our strategies and accomplishments in governance, social responsibility, and environmental stewardship.”

 

For more details on WuXi XDC’s ESG initiatives and to access the full report, please click here.

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?